Forward, with the science.
Shop protocolsWhat’s movingin the literature.
PubMedReal-world use of submaximal doses of long-acting GLP-1 receptor agonist semaglutide in…·Jun 4, 2026ClinicalTrials.govPhase 3 · A Study of Orforglipron for the Maintenance of Body Weight Reductio… (completed)·Jun 4, 2026ClinicalTrials.govPhase 2 · Randomized Double Blinded Placebo-Controlled w/Semaglutide to Preve… (recruiting)·Jun 4, 2026ClinicalTrials.govPhase NA · Weight Loss in Adults Using Semaglutide (Real-world Study) (recruiting)·Jun 4, 2026ClinicalTrials.govEARLY_PHASE1 · GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, C… (not yet recruiting)·Jun 4, 2026ClinicalTrials.govNA · Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Struct… (not yet recruiting)·Jun 4, 2026ClinicalTrials.govPhase 3 · A Master Protocol of Multiple Agents in Adults With Metabolic Dysfu… (recruiting)·Jun 4, 2026ClinicalTrials.govPhase 2 · Tirzepatide in Women With Obesity and Endometrial Intra-epithelial … (not yet recruiting)·Jun 4, 2026ClinicalTrials.govPhase 2 · Resistance Exercise and Incretin Mimetic for Cardiometabolic Health… (recruiting)·Jun 4, 2026ClinicalTrials.govPhase 3 · A Study of Retatrutide (LY3437943) in Participants Without Type 2 D… (recruiting)·Jun 4, 2026ClinicalTrials.govPhase 1 · Double-blind Placebo Controlled Study to Evaluate the Effect of NAD… (recruiting)·Jun 4, 2026PubMedSemaglutide in Adolescents Living With Obesity: A Real-World Data Study Exploring…·Jun 3, 2026PubMedReal-world use of submaximal doses of long-acting GLP-1 receptor agonist semaglutide in…·Jun 4, 2026ClinicalTrials.govPhase 3 · A Study of Orforglipron for the Maintenance of Body Weight Reductio… (completed)·Jun 4, 2026ClinicalTrials.govPhase 2 · Randomized Double Blinded Placebo-Controlled w/Semaglutide to Preve… (recruiting)·Jun 4, 2026ClinicalTrials.govPhase NA · Weight Loss in Adults Using Semaglutide (Real-world Study) (recruiting)·Jun 4, 2026ClinicalTrials.govEARLY_PHASE1 · GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, C… (not yet recruiting)·Jun 4, 2026ClinicalTrials.govNA · Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Struct… (not yet recruiting)·Jun 4, 2026ClinicalTrials.govPhase 3 · A Master Protocol of Multiple Agents in Adults With Metabolic Dysfu… (recruiting)·Jun 4, 2026ClinicalTrials.govPhase 2 · Tirzepatide in Women With Obesity and Endometrial Intra-epithelial … (not yet recruiting)·Jun 4, 2026ClinicalTrials.govPhase 2 · Resistance Exercise and Incretin Mimetic for Cardiometabolic Health… (recruiting)·Jun 4, 2026ClinicalTrials.govPhase 3 · A Study of Retatrutide (LY3437943) in Participants Without Type 2 D… (recruiting)·Jun 4, 2026ClinicalTrials.govPhase 1 · Double-blind Placebo Controlled Study to Evaluate the Effect of NAD… (recruiting)·Jun 4, 2026PubMedSemaglutide in Adolescents Living With Obesity: A Real-World Data Study Exploring…·Jun 3, 2026
Bestseller.
↑ +18% this week
Semaglutide
GLP-1 receptor agonist · Subcutaneous
Five years of post-approval real-world data. The maturity benchmark every other peptide is still trying to earn.
Catalog
Peptides.
Science signal
Evidence.
Maturity and adoption per molecule.
Semaglutide
~est. 4.2M U.S. adults
Tirzepatide
~est. 2.1M U.S. adults
Retatrutide
Phase 3 · ~est. 800K at launch
BPC-157
Wellness market · ~150K current
Cagrilintide
Phase 2 · ~est. 500K eligible
NAD+
Wellness market · ~320K current
Signal
Last 30 days · 5 itemsMEDIAMay 20·Fox News · Health
Retatrutide preserves muscle during weight loss
Huberman on triple agonist mechanism and LPS contamination risk in gray-market peptides
→ foxnews.com
POLICYMay 12·OneTwenty
14 of 19 Category 2 peptides moving back to Category 1
RFK Jr announced reversal on Joe Rogan Experience #2461 (Feb 27 2026)
→ onetwenty.com
PODCASTMay 8·NYT · Ezra Klein Show
The Dawn of the Ozempic Era
Julia Belluz on the GLP-1 cultural and clinical inflection point
→ nytimes.com
JOURNALMay 15·JAMA
Unapproved peptide products: clinician guidance
JAMA editorial on prescribing standards for non-FDA-approved peptides
→ facebook.com
VIDEOMay 15·YouTube · Dialed In Health
Muscle Loss, Ozempic Butt, and the Fix
Clinical commentary on body composition during GLP-1 therapy
→ youtube.com
STUDYsignal table · last 30d
NAD+ 36 new PubMed
TRENDgoogle_trend · 30d vs prior 60d